FDA approves 1st drug for hypertrophic cardiomyopathy

The FDA on April 28 approved Bristol Myers Squibb's Camzyos, the first drug to target the cause of obstructive hypertrophic cardiomyopathy. 

Read the full post at Becker's Hospital Review - Healthcare News